ProMIS Neurosciences Inc PMN

Healthcare Biotechnology

ProMIS Neurosciences Inc. is a clinical-stage biotechnology company. It is focused on generating and developing antibody therapeutics selectively targeting toxic misfolded proteins in neurodegenerative diseases such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and multiple system atrophy (MSA). Its proprietary target discovery engine applies a thermodynamic, computational discovery platform-ProMIS and Collective Coordinates-to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this approach, the Company is developing novel antibody therapeutics for AD, ALS and MSA. Its product candidates are PMN310, PMN267, and PMN442. The PMN310 is a monoclonal antibody designed to treat AD by selectively targeting toxic, misfolded oligomers of amyloid-beta. PMN267 product candidate targeting ALS. PMN442 is a drug candidate being developed for MSA designed to selectively target and protect against pathogenic a-syn species.

NDAQ:PMN - Post by User

ProMIS Neurosciences Inc > Incompetent CEO

<< Previous

Bullboard Posts

Next >>

Comment by DavidKingCanadaon Dec 22, 2021 3:16pm

132 Views

Post# 34255746

RE:Incompetent CEO

goldtech wrote: You are correct M101 with Goldstein leaving and pilfering the coffers it's a great day for shareholders. Six years of totally ruining the share capital of this company has finally caught up to his abuse to the investors.Gene was the brains not Elliott and now let's get a powerhouse CEO and put this company in dollars not pennies.

Goldtech's first post and all he does is bash management and nothing else.

<< Previous

Bullboard Posts

Next >>

How one company is disrupting PoC testing